Building hope through science.

Kingdom Therapeutics is at the forefront of groundbreaking research on the link between the gut, the brain, and the endocannabinoid system, initially with a focus on ASD.

KT-20610

Our groundbreaking science is looking at the role of the gut-brain-endocannabinoid axis in profound autism and we are investigating if our drug, KT-20610 can improve both behavioural and gastrointestinal symptoms in ASD.

Experience at every level.

We are a team of leading experts in the pharmaceutical industry, pharmaceutical development, the science of cannabinoids, healthcare, and pharmaceutical intellectual property who are working alongside representatives from our target patient community.

Newsroom.